Health Care [ 9/12 ] | Health Care Equipment & Supplies [ 56/74 ]
NASDAQ | Common Stock
Aspira Women's Health Inc., together with its subsidiaries, discovers, develops, and commercializes of noninvasive AI-powered diagnostic tests for gynecologic diseases in the United States.
The company's products include Ova1Plus, a qualitative serum test to assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker test intended to maintain Ova1's high sensitivity; and OvaWatch, a laboratory developed tests to assist in the initial clinical assessment of malignancy risk in all women thought to have an indeterminate or benign adnexal mass.
It is also developing OvaMDx, a multi-marker test that combines serum proteins, clinical data, and miRNA for assessing the risk of ovarian cancer in women with an adnexal mass; EndoCheck, a protein biomarker designed to identify ovarian endometriomas; and EndoMDx for the identification of endometriosis.
The company also operates Aspira Labs, a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease.
The company serves physicians, physician office laboratories, and national and regional laboratories.
The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC.
It has a research agreement with Harvard's Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University of Lodz for the generation of a multi-omic, non-invasive diagnostic aid to identify endometriosis based on circulating miRNAs and proteins; and a strategic alliance with Quest Diagnostics, Incorporated.
The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020.
Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 26, 25 | -0.09 Increased by +71.67% | -0.22 Increased by +61.36% |
| Nov 11, 24 | -0.24 Increased by +49.69% | -0.24 Decreased by -0.63% |
| Aug 12, 24 | -0.28 Increased by 0.00% | -0.30 Increased by +6.67% |
| May 15, 24 | -0.39 Increased by +96.44% | -0.33 Decreased by -18.18% |
| Mar 28, 24 | -0.30 Decreased by -650.00% | -0.45 Increased by +33.33% |
| Nov 13, 23 | -0.48 Decreased by -500.00% | -0.51 Increased by +5.88% |
| Aug 14, 23 | -0.28 Decreased by -300.00% | -0.55 Increased by +49.09% |
| May 11, 23 | -10.95 Decreased by -13.59 K% | -0.75 Decreased by -1.36 K% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 2.35 M Increased by +5.95% | -1.39 M Increased by +70.51% | Decreased by -59.09% Increased by +72.16% |
| Sep 30, 24 | 2.26 M Decreased by -9.39% | -3.55 M Decreased by -53.09% | Decreased by -157.16% Decreased by -68.96% |
| Jun 30, 24 | 2.42 M Increased by +4.62% | -3.53 M Increased by +44.31% | Decreased by -145.69% Increased by +46.77% |
| Mar 31, 24 | 2.15 M Increased by 0.00% | -4.63 M Increased by +0.34% | Decreased by -215.00% Increased by +0.34% |
| Sep 30, 23 | 2.22 M Increased by +7.00% | -4.71 M Decreased by -3.25% | Decreased by -212.27% Increased by +3.51% |
| Jun 30, 23 | 2.49 M Increased by +20.57% | -2.32 M Increased by +71.97% | Decreased by -93.01% Increased by +76.75% |
| Mar 31, 23 | 2.32 M Increased by +22.35% | -6.34 M Increased by +31.76% | Decreased by -273.70% Increased by +44.22% |
| Dec 31, 22 | 2.15 M Increased by +16.32% | -4.64 M Increased by +48.16% | Decreased by -215.75% Increased by +55.44% |